MAPT and Alzheimer disease: We therefore assessed the independent and combined predictive effects of baseline neuroimaging biomarkers for tau pathology (18F-AV-1451 PET), neuroinflammation (11C-PK11195 PET) and brain atrophy (structural MRI) on longitudinal cognitive changes over a period of 3 years in the clinical spectrum of Alzheimer’s disease.